Rivernorth Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Rivernorth Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-110,837	Closed	-$6.65K	–	797
2022 Q4	$6.65K	Hold	110,837	–	–	﹤0.01%	582
2022 Q3	$7K	Hold	110,837	–	–	﹤0.01%	720
2022 Q2	$4K	Hold	110,837	–	–	﹤0.01%	748
2022 Q1	$27K	Sell	110,837 -1,662	-1%	-$530	﹤0.01%	647
2021 Q4	$73K	Hold	112,499	–	–	﹤0.01%	520
2021 Q3	$74K	Buy	+112,499	New	+$83.7K	﹤0.01%	421

Rivernorth Capital Management's BIOTW Position: Q1 2023 in Review

Rivernorth Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 110,837 shares — an estimated $6.65K sold.

Rivernorth Capital Management first reported a position in BIOTW in Q3 2021 and held it in 6 quarters. The position peaked at $74K in Q3 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Rivernorth Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Rivernorth Capital Management sold 110,837 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $6.65K.
Rivernorth Capital Management first reported a position in Biotech Acquisition Company Warrant in Q3 2021 and held it in 6 quarters.
Rivernorth Capital Management's Biotech Acquisition Company Warrant position peaked at $74K in Q3 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Rivernorth Capital Management's 13F filing for Q1 2023, filed 15 May 2023.